首页> 外文期刊>Medical oncology >Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.
【24h】

Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

机译:瑞典肺癌放射线研究小组:非小细胞肺癌患者诊断时贫血,血小板增多和白细胞增多的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (>50?Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb??9.0?×?10(9)/L and??350?×?10(9)/L and?<350?×?10(9)/L, the median survival was 11.2 and 14.9?months, respectively (p?
机译:需要改善非小细胞肺癌(NSCLC)的预后和预测指标。目前,主要重点是遗传预测标记,而与造血相关的标准血液变量的预后价值受到相对有限的关注。研究在诊断时接受治疗的放射治疗(> 50? Gy),被纳入研究范围。研究了WBC,Plt,Hgb,性别,诊断年龄,分期,手术和一线化疗与总生存率的关系。对于Hgb 110?g / L和Hgb≥≥110?g / L的患者,中位生存期分别为11.2和14.5?个月(p = 0.0032)。对于WBC≥> 9.0××10(9)/ L和≥<9.0××10(9)/ L,中位生存期分别为11.6和15.4-个月(p << 0.0001)。对于Plt≥>350≤×10(9)/ L和≤<350≤×10(9)/ L,中位生存期分别为11.2和14.9个月(p << 0.0001)。三种指标均具有病理结果的患者的中位生存期是三种指标均处于正常水平的患者的中位生存期的一半(分别为8.0和16.0?months(p?<0.0001))。这些结果表明标准的血液学变量可以作为临床医生在治疗强度和患者信息方面的决策指南。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号